These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 12716243)

  • 1. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
    Szegedi A; Müller MJ; Anghelescu I; Klawe C; Kohnen R; Benkert O
    J Clin Psychiatry; 2003 Apr; 64(4):413-20. PubMed ID: 12716243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mirtazapine compared with paroxetine in major depression.
    Benkert O; Szegedi A; Kohnen R
    J Clin Psychiatry; 2000 Sep; 61(9):656-63. PubMed ID: 11030486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the clinical efficacy of mirtazapine.
    Benkert O; Muller M; Szegedi A
    Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S23-6. PubMed ID: 12404666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirtazapine versus selective serotonin reuptake inhibitors.
    Thompson C
    J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.
    Schatzberg AF; Kremer C; Rodrigues HE; Murphy GM;
    Am J Geriatr Psychiatry; 2002; 10(5):541-50. PubMed ID: 12213688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.
    Fava M; Dunner DL; Greist JH; Preskorn SH; Trivedi MH; Zajecka J; Cohen M
    J Clin Psychiatry; 2001 Jun; 62(6):413-20. PubMed ID: 11465517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population.
    Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA;
    J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does mirtazapine have a more rapid onset than SSRIs?
    Quitkin FM; Taylor BP; Kremer C
    J Clin Psychiatry; 2001 May; 62(5):358-61. PubMed ID: 11411818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
    Hong CJ; Hu WH; Chen CC; Hsiao CC; Tsai SJ; Ruwe FJ
    J Clin Psychiatry; 2003 Aug; 64(8):921-6. PubMed ID: 12927007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
    Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
    Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    Wheatley DP; van Moffaert M; Timmerman L; Kremer CM
    J Clin Psychiatry; 1998 Jun; 59(6):306-12. PubMed ID: 9671343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
    Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
    Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
    Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Care of depressed patients with anxiety symptoms.
    Nutt DJ
    J Clin Psychiatry; 1999; 60 Suppl 17():23-7; discussion 46-8. PubMed ID: 10446738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
    Pallanti S; Quercioli L; Bruscoli M
    J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.
    Kato M; Takekita Y; Koshikawa Y; Sakai S; Bandou H; Nishida K; Sunada N; Onohara A; Hatashita Y; Serretti A; Kinoshita T
    J Psychiatr Res; 2017 Jun; 89():97-104. PubMed ID: 28213170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.